Delivery Order SPE2DB20D2002-SPE2DB25FL69E
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,082.99 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pen injectors on July 24, 2025. This firm fixed-price delivery order, which is a child contract under a larger indefinite delivery vehicle, represents a routine pharmaceutical procurement for military healthcare needs. The contract was competitively awarded without set-aside designation and specifies performance at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pen injectors on June 2, 2025, with a completion date of June 3, 2025. This competitively awarded, firm fixed-price delivery order represents a supply of the diabetes medication to support federal healthcare needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,496.91 delivery order to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 ml pen injections on May 30, 2025, with a completion date of June 2, 2025. This firm fixed price contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,644.62 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on July 25, 2025, with a completion date of July 28, 2025. This is a firm fixed-price, non-competitive delivery order with no set-aside designation, issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award represents a standard pharmaceutical procurement supporting the federal government's...
- The Defense Logistics Agency (DLA) awarded a $4,081.35 delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 ml pen injections on April 25, 2025, with completion scheduled for April 28, 2025. This firm fixed price contract represents a child order under AmerisourceBergen's larger $999.99 billion Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and running through December 2026. The delivery order was competitively awarded with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,343.84 to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 ml pen injectors on September 10, 2025, with completion scheduled for September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $111,508.90 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors on September 5, 2025, with completion expected by September 8, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers pharmaceutical supply for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,193.99 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injectors, with an ultimate completion date of August 12, 2025. This competitive award was issued on August 11, 2025, under a firm fixed price contract type with no set-aside designation. The performance location is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,899.65 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on August 25, 2025, with completion targeted for August 26, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract procures a diabetes medication used across military and federal healthcare systems...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,769.69 to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pen injectors on August 22, 2025, with completion expected by August 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers the supply of this diabetes medication, which falls within...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB25FL69EDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,773.80 to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pen injections on August 20, 2025, with completion by August 21, 2025. This firm fixed-price delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), represents a non-competitive set-aside award for a pharmaceutical product commonly used in diabetes management. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's comprehensive $999,999,999.00 IDC with the DLA, which runs through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems worldwide. The company's track record with the DLA demonstrates its capability to fulfill federal medical procurement requirements efficiently through firm fixed-price delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 8/20/25 |